Allos Therapeutics Inc.

Westminster, CO, United States

Allos Therapeutics Inc.

Westminster, CO, United States

Time filter

Source Type

News Article | May 12, 2017
Site: marketersmedia.com

Malignant Lymphoma Market Information, by types (Hodgkin lymphoma and Non Hodgkin lymphoma), by treatment (chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others) - Forecast to 2022 Pune, India - May 11, 2017 /MarketersMedia/ — Malignant Lymphoma Market Information, by types (Hodgkin lymphoma and Non Hodgkin lymphoma), by treatment (chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others) - Forecast to 2022 The lymphatic system runs throughout our bodies. Cancers that develop anywhere in body’s lymphatic system are called as lymphoma and if they have the ability to spread in the body, they are called malignant lymphoma. The most common symptom of the lymphoma is swollen glands. Men are more prone to lymphoma compared to women for the reason unknown. Globally the market for malignant lymphoma is increasing rapidly. Get a sample copy @ https://www.marketresearchfuture.com/sample_request/1861 . Study objectives of Malignant Lymphoma Market: • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the malignant lymphoma market. • To provide insights about factors affecting the market growth • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa. • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segments by type, by treatment and its sub-segments. • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global malignant lymphoma market. Complete Report Available at https://www.marketresearchfuture.com/reports/malignant-lymphoma-market . Intended Audience • Malignant lymphoma drug manufacturers & Suppliers • Contract Research Organizations (CROs) • Research and Development (R&D) Companies • Government Research Laboratories • Independent Research Laboratories • Government and Independent Regulatory Authorities • Market Research and Consulting Service Providers • Academic Institutes and Universities Malignant lymphoma market has been segmented on the basis of types which comprises of Hodgkin lymphoma and non-Hodgkin lymphoma. On the basis of treatments, market is segmented into chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others. Globally North America is the largest market for malignant lymphoma. Europe is the second-largest market. Furthermore Asia pacific market is expected to be the fastest growing market for malignant lymphoma. Request for Discount at https://www.marketresearchfuture.com/check-discount/1861 Some of the key players in this market are: • Abbott Laboratories • ABIOGEN PHARMA S.p.A. • Actelion Pharmaceuticals • Aeterna Zentaris, Inc. • Allos Therapeutics • Astellas Pharma • Bristol-Myers Squibb Company • Celgene Corporation • Eli Lilly and Company • Genmab • Inovio Pharmaceuticals • Johnson & Johnson • Merck & Co. Inc. • Novartis • Onyx Pharmaceuticals • Roche • Seattle Genetics North America • US • Canada • Europe Western Europe • Germany • France • Italy • Spain • UK • Rest of Western Europe • Eastern Europe Asia • China • India • Japan • South Korea • Rest of AsiaPacific Middle East & Africa The report for Malignant Lymphoma Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions List of Tables TABLE 1 GLOBAL MALIGNANT LYMPHOMA MARKET, BY TYPES, 2013-2022 (USD MILLION) TABLE 2 GLOBAL MALIGNANT LYMPHOMA MARKET, BY TREATMENT, 2013-2022 (USD MILLION) TABLE 3 GLOBAL MALIGNANT LYMPHOMA MARKET, BY REGION, 2013-2022 (USD MILLION) List of Figures FIGURE 1 RESEARCH PROCESS FIGURE 2 PORTERS FIVE FORCES MODEL FIGURE 3 GLOBAL MALIGNANT LYMPHOMA MARKET, BY TYPES FIGURE 4 GLOBAL MALIGNANT LYMPHOMA MARKET, BY TREATMENT FIGURE 5 GLOBAL MALIGNANT LYMPHOMA MARKET, BY REGION FIGURE 6 GLOBAL MALIGNANT LYMPHOMA MARKET: COMPANY SHARE ANALYSIS, 2015 (%) Contact Info:Name: Akash AnandEmail: Akash.Anand@Marketresearchfuture.ComOrganization: Market Research FutureAddress: Market Research Future Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, IndiaPhone: +1 646 845 9312Source URL: http://marketersmedia.com/malignant-lymphoma-market-research-report-global-forecast-to-2022/198744For more information, please visit https://www.marketresearchfuture.com/reports/malignant-lymphoma-marketSource: MarketersMediaRelease ID: 198744


Horwitz S.M.,Sloan Kettering Cancer Center | Kim Y.H.,Stanford University | Foss F.,Yale Cancer Center | Zain J.M.,New York University | And 10 more authors.
Blood | Year: 2012

Systemic treatment for cutaneous T-cell lymphoma (CTCL) involves the use of less aggressive, well-tolerated therapies. Pralatrexate is a novel antifolate with high affinity for reduced folate carrier-1.Adose de-escalation strategy identified recommended pralatrexate dosing for patients with CTCL that demonstrated high activity, good rates of disease control, and an acceptable toxicity profile for continuous long-term dosing. Eligibility included mycosis fungoides, Sézary syndrome, or primary cutaneous anaplastic large cell lymphoma, with disease progression after > 1 prior systemic therapy. The starting dose and schedule was 30 mg/m2/wk intravenously for 3 of 4 (3/4) weeks. Subsequent starting doses were 20, 15, and 10 mg/m2/wk for 3/4 or 2 of 3 (2/3) weeks. Response was evaluated by the modified severity-weighted adjustment tool. Fiftyfour patients were treated. The recommended regimen was identified as 15 mg/ m2/wk for 3/4 weeks and was explored in the expansion cohort. In 29 patients treated overall with the recommended dosing regimen, the median number of prior systemic therapies was 4. Pralatrexate was administered for a median of 4 cycles; response rate was 45%. The most common grade 3 adverse event (AE) was mucositis (17%); the only grade 4 AE was leukopenia (3%). Pralatrexate 15 mg/m2/wk for 3/4 weeks shows high activity with acceptable toxicity in patients with relapsed/refractory CTCL. © 2012 by The American Society of Hematology.


The present invention relates to diastereomers of 10-propargyl-10-deazaminopterin, compositions comprising optically pure diastereomers of 10-propargyl-10-deazaminopterin, in particular the two (R,S) diastereomers about the C10 position. Methods of preparation of these diastereomers, compositions containing them, and their use for the treatment of conditions related to inflammatory disorders and cancer are also disclosed.


The present invention relates to diastereomers of 10-propargyl-10-deazaminopterin, compositions comprising optically pure diastereomers of 10-propargyl-10-deazaminopterin, in particular the two (R,S) diastereomers about the C10 position. Methods of preparation of these diastereomers, compositions containing them, and their use for the treatment of conditions related to inflammatory disorders and cancer are also disclosed.


The present invention includes a method to reverse the trend towards progressive resistance to consecutive treatments for T-cell lymphoma in a patient. This method includes selecting a patient having T-cell lymphoma, wherein the patient has had at least one prior treatment for T-cell lymphoma, wherein the prior treatment comprises non-10-propargyl-10-deazaaminopterin; and administering to the patient a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaminopterin, whereby the trend towards progressive resistance is reversed.


The present invention relates to compositions comprising a combination of 10-propargyl-10-deazaaminopterin and an EGFR Kinase inhibitor, including erlotinib, for treatment of non-small cell lung cancer, and methods of treatment for non-small cell lung cancer in a patient in need thereof comprising administering for combination of 10-propargyl-10-deazaaminopterin and an EGFR Kinase inhibitor, including erlotinib, for treatment of non-small cell lung cancer.


Trademark
Allos Therapeutics Inc. | Date: 2011-10-11

Pharmaceutical preparations for the treatment of cancer.


The present invention relates to diastereomers of 10-propargyl-10-deazaminopterin, compositions comprising optically pure diastereomers of 10-propargyl-10-deazaminopterin, in particular the two (R,S) diastereomers about the C10 position. Methods of preparation of these diastereomers, compositions containing them, and their use for the treatment of conditions related to inflammatory disorders and cancer are also disclosed.


The present invention relates to a method for treating a methotrexate-resistant disorder in an individual, wherein the method comprises administering to the individual an effective amount of 10-propargyl-10-deazaminopterin or its pharmaceutically acceptable salts.


The present invention relates to a method for assessing the sensitivity of a patients cancer to treatment with 10-propargyl-10-deazaminopterin and a method for selecting a patient for treatment of cancer with 10-propargyl-10-deazaminopterin, by determining the amount of a EGFR or other growth factor expressed by the cancer and comparing the amount with the amount of EGFR or other growth factor expressed by a reference cancer.

Loading Allos Therapeutics Inc. collaborators
Loading Allos Therapeutics Inc. collaborators